Advertisement

Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis

  • Sheng-li Yang (杨盛力)
  • Quan-guang Ren (任全广)
  • Lu Wen (文 璐)
  • Jian-li Hu (胡建莉)Email author
Article

Summary

Hypoxia-inducible factor-1 alpha (HIF-1α) plays a vital role in the initiation, evaluation and prognosis in lung cancer. The prognostic value of HIF-1α reported in diverse study remains disputable. Accordingly, a meta-analysis was implemented to further understand the prognostic role of HIF-1α in lung cancer. The relationship between HIF-1α and the clinicopathological characteristics and prognosis of lung cancer were investigated by a meta-analysis. PubMed and Embase were searched from their inception to January 2015 for observational studies. Fixed-effects or random-effects meta-analyses were used to calculate odds ratios and 95% confidence intervals of different comparisons. A total of 20 studies met the criteria. The results showed that HIF-1α expression in lung cancer tissues was significantly higher than that in normal lung tissues. Expression of HIF-1α in patients with squamous cell carcinoma was significantly higher than that of patients with adenocarcinomas. Similarly, non-small cell lung cancer (NSCLC) patients had higher HIF-1α expression than small cell lung cancer (SCLC) patients. Moreover, lymph node metastasized tissues had higher HIF-1α expression than non-lymph node metastasized tissues. A high level HIF-1α expression was well correlated with the expression of vascular endothelial growth factor and epidermal growth factor receptor in the NSCLC. Notably, NSCLC or SCLC patients with positive HIF-1α expression in tumor tissues had lower overall survival rate than patients with negative HIF-1α expression. It was suggested that HIF-1α expression may be a prognostic biomarker and a potential therapeutic target for lung cancer.

Key words

non-small cell lung cancer small cell lung cancer hypoxia-inducible factor-1 alpha vascular endothelial growth factor epidermal growth factor receptor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1): 11–30CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 2012, 62(4): 220–241CrossRefPubMedGoogle Scholar
  3. 3.
    Zhong H, Semenza GL, Simons JW, et al. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev, 2004, 28(2): 88–93CrossRefPubMedGoogle Scholar
  4. 4.
    Volm M, Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res, 2000, 20(3): 1527–1533PubMedGoogle Scholar
  5. 5.
    Giatromanolaki A, Oukourakis M, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer, 2001, 85(6): 881–890CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lee CH, Lee MK, Kang CD, et al. Differential expression of hypoxia inducible factor-1 alpha and tumor cell proliferation between squamous cell carcinomas and adenocarcinomas among operable non-small cell lung carcinomas. J Korean Med Sci, 2003, 18(2): 196–203CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hirami Y, Aoe M, Tsukuda K, et al. Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1alpha in non-small cell lung cancers. Cancer Lett, 2004, 214(2): 157–164CrossRefPubMedGoogle Scholar
  8. 8.
    Swinson DE, Jones JL, Cox G, et al. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer, 2004, 111(1): 43–50CrossRefPubMedGoogle Scholar
  9. 9.
    Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF-1alpha, CAIX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer, 2005, 49(3): 325–335CrossRefPubMedGoogle Scholar
  10. 10.
    Enatsu S, Iwasaki A, Shirakusa T, et al. Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung. Eur J Cardiothorac Surg, 2006, 29(6): 891–895CrossRefPubMedGoogle Scholar
  11. 11.
    Zuo S, Ji Y, Wang J, et al. Expression and clinical implication of HIF-1alpha and VEGF-C in non-small cell lung cancer. J Huazhong Univ Sci Technolog Med Sci, 2008, 28(6): 674–676CrossRefPubMedGoogle Scholar
  12. 12.
    Chen YQ, Zhao CL, Li W. Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer. J Exp Clin Cancer Res, 2009, 28(1): 29CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hung JJ, Yang MH, Hsu HS, et al. Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax, 2009, 64(12): 1082–1089CrossRefPubMedGoogle Scholar
  14. 14.
    Ioannou M, Papamichali R, Kouvaras E, et al. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung, 2009, 187(5): 321–329CrossRefPubMedGoogle Scholar
  15. 15.
    Yohena T, Yoshino I, Takenaka T, et al. Upregulation of hypoxia-inducible factor-1alpha mRNA and its clinical significance in non-small cell lung cancer. J Thorac Oncol, 2009, 4(3): 284–290CrossRefPubMedGoogle Scholar
  16. 16.
    Andersen S, Eilertsen M, Donnem T, et al. Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer, 2011, 72(3): 294–302CrossRefPubMedGoogle Scholar
  17. 17.
    Park S, Ha SY, Cho HY, et al. Prognostic implications of hypoxia-inducible factor-1alpha in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer, 2011, 72(1): 100–107CrossRefPubMedGoogle Scholar
  18. 18.
    Wu XH, Qian C, Yuan K. Correlations of hypoxia-inducible factor-1alpha/hypoxia-inducible factor-2alpha expression with angiogenesis factors expression and prognosis in non-small cell lung cancer. Chin Med J (Engl), 2011, 124(1): 11–18Google Scholar
  19. 19.
    Karetsi E, Ioannou MG, Kerenidi T, et al. Differential expression of hypoxia-inducible factor 1alpha in non-small cell lung cancer and small cell lung cancer. Clinics (Sao Paulo), 2012, 67(12): 1373–1378CrossRefGoogle Scholar
  20. 20.
    Lee GW, Go SI, Cho YJ, et al. Hypoxia-inducible factor-1alpha and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study. J Thorac Oncol, 2012, 7(3): 528–534CrossRefPubMedGoogle Scholar
  21. 21.
    Munksgaard PM, Johansson ME, Monsef N, et al. HIF-2alpha expression is suppressed in SCLC cells, which survive in moderate and severe hypoxia when HIF-1alpha is repressed. Am J Pathol, 2012, 180(2): 494–504CrossRefGoogle Scholar
  22. 22.
    Luan Y, Gao C, Miao Y, et al. Clinicopathological and prognostic significance of HIF-1alpha and HIF-2alpha expression in small cell lung cancer. Pathol Res Pract, 2013, 209(3): 184–189CrossRefPubMedGoogle Scholar
  23. 23.
    Ping W, Jiang WY, Chen WS, et al. Expression and significance of hypoxia inducible factor-1alpha and lysyl oxidase in non-small cell lung cancer. Asian Pac J Cancer Prev, 2013, 14(6): 3613–3618CrossRefPubMedGoogle Scholar
  24. 24.
    Minakata K, Takahashi F, Nara T, et al. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. Cancer Sci, 2012, 103(11): 1946–1954CrossRefPubMedGoogle Scholar
  25. 25.
    Honguero MA, Arnau OA, Figueroa AS, et al. Prognostic value of the expression of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha in patients undergoing surgery for non-small cell lung cancer. Med Clin (Barc), 2014, 142(10): 432–437CrossRefGoogle Scholar
  26. 26.
    Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA, 2000, 283(15): 2008–2012CrossRefPubMedGoogle Scholar
  27. 27.
    Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414): 557–560CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials, 1986, 7(3): 177–188CrossRefPubMedGoogle Scholar
  29. 29.
    Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol, 2007, 25(35): 5562–5569CrossRefPubMedGoogle Scholar
  30. 30.
    Jubb AM, Pham TQ, Hanby AM, et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol, 2004, 57(5): 504–512CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ghattass K, Assah R, El-Sabban M, et al. Targeting hypoxia for sensitization of tumors to radio-and chemotherapy. Curr Cancer Drug Targets, 2013, 13(6): 670–685CrossRefPubMedGoogle Scholar
  32. 32.
    Cao S, Yang S, Wu C, et al. Protein expression of hypoxia-inducible factor-1 alpha and hepatocellular carcinoma: a systematic review with meta-analysis. Clin Res Hepatol Gastroenterol, 2014, 38(5): 598–603CrossRefPubMedGoogle Scholar
  33. 33.
    Baba Y, Nosho K, Shima K, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol, 2010, 176(5): 2292–2301CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hoffmann AC, Mori R, Vallbohmer D, et al. High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia, 2008, 10(7): 674–679CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Tang CM, Yu J. Hypoxia-inducible factor-1 as a therapeutic target in cancer. J Gastroenterol Hepatol, 2013, 28(3): 401–405CrossRefPubMedGoogle Scholar
  36. 36.
    Chen D, Zhang YJ, Zhu KW, et al. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol, 2013, 34(3): 1895–1899CrossRefPubMedGoogle Scholar
  37. 37.
    Lo HW. Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discov Med, 2010, 10(50): 44–51PubMedPubMedCentralGoogle Scholar
  38. 38.
    Peng XH, Karna P, Cao Z, et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem, 2006, 281(36): 25903–25914CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Swinson DE, O'Byrne KJ. Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. Clin Lung Cancer, 2006, 7(4): 250–256CrossRefPubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Sheng-li Yang (杨盛力)
    • 1
  • Quan-guang Ren (任全广)
    • 1
  • Lu Wen (文 璐)
    • 1
  • Jian-li Hu (胡建莉)
    • 1
    Email author
  1. 1.Cancer Center, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations